These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8461237)

  • 1. Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans.
    Toyama H; Ichise M; Ballinger JR; Fornazzari L; Kirsh JC
    Ann Nucl Med; 1993 Feb; 7(1):29-38. PubMed ID: 8461237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W; Grundmann M; Huber G
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.
    Tatsch K; Schwarz J; Oertel WH; Kirsch CM
    Nucl Med Commun; 1991 Aug; 12(8):699-707. PubMed ID: 1838142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease.
    Ichise M; Toyama H; Fornazzari L; Ballinger JR; Kirsh JC
    J Nucl Med; 1993 Aug; 34(8):1274-81. PubMed ID: 8326384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
    Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
    Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
    Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
    Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism.
    Schwarz J; Antonini A; Tatsch K; Kirsch CM; Oertel WH; Leenders KL
    Nucl Med Commun; 1994 Oct; 15(10):806-13. PubMed ID: 7838444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic SPECT in two healthy volunteers to determine the optimal time for in vivo D2 dopamine receptor imaging with 123I-IBZM using the rotating gamma camera.
    Verhoeff NP; Brücke T; Podreka I; Bobeldijk M; Angelberger P; Van Royen EA
    Nucl Med Commun; 1991 Aug; 12(8):687-97. PubMed ID: 1838141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].
    Saur HB; Bartenstein P; Schober O; Oberwittler C; Lerch H; Masur H
    Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease.
    Pirker W; Asenbaum S; Wenger S; Kornhuber J; Angelberger P; Deecke L; Podreka I; Brücke T
    J Nucl Med; 1997 Nov; 38(11):1711-7. PubMed ID: 9374338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
    Leslie WD; Abrams DN; Greenberg CR; Hobson D
    J Nucl Med; 1996 Oct; 37(10):1589-91. PubMed ID: 8862288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain.
    Verhoeff NP; Bobeldijk M; Feenstra MG; Boer GJ; Maas MA; Erdtsieck-Ernste E; de Bruin K; van Royen EA
    Int J Rad Appl Instrum B; 1991; 18(8):837-46. PubMed ID: 1839302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
    de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
    Brücke T; Podreka I; Angelberger P; Wenger S; Topitz A; Küfferle B; Müller C; Deecke L
    J Cereb Blood Flow Metab; 1991 Mar; 11(2):220-8. PubMed ID: 1671782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects.
    Schlösser R; Schlegel S; Hiemke C; Nickel O; Bockisch A; Rao ML; Hahn K
    Psychiatry Res; 1997 Sep; 75(2):103-14. PubMed ID: 9351492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vivo characteristics of IBZM in rat brains: an agent for quantitative SPECT imaging of dopamine D2 receptors. Preparation of 125I-IBZM and its biodistribution and kinetic properties].
    Matsumura K; Toyama H; Nakashima H; Ichise M; Kurami M; Nakagawa T; Maeda H; Takeuchi A; Koga S
    Kaku Igaku; 1994 May; 31(5):513-9. PubMed ID: 8028224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease.
    Cordes M; Henkes H; Laudahn D; Bräu H; Kramp W; Girke W; Hierholzer J; Eichstädt H; Felix R
    Eur J Radiol; 1991; 12(3):182-6. PubMed ID: 1830273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vivo characteristics of IBZM in rat brains: an agent for quantitative SPECT imaging of D2 dopamine receptors--a basis for semiquantitative measurement of the receptor density using equilibrium analysis].
    Toyama H; Matsumura K; Nakashima H; Ichise M; Kurami M; Nakagawa T; Maeda H; Takeuchi A; Koga S
    Kaku Igaku; 1994 Sep; 31(9):1117-20. PubMed ID: 7967197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.
    Jauss M; Krack P; Franz M; Klett R; Bauer R; Gallhofer B; Dorndorf W
    Mov Disord; 1996 Nov; 11(6):726-8. PubMed ID: 8914102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.